Characterization of biomarkers to identify "responders" and "non-responders" in chronic spontaneous urticaria (CSU) therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024872

Enrollment

Registered

2021-03-19

Start date

2021-03-19

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic spontaneous urticaria L50.8

Interventions

Group 1: In the planned study, miRNAs in plasma of CSU patients before and during omalizumab therapy will be investigated in parallel to IgE levels. A flow cytometric method will be used, which allows

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with spontaneous urtikatia who are eligible for omalizumab therapy.

Exclusion criteria

Exclusion criteria: Subjects younger than 18 years and older than 65 years.

Design outcomes

Primary

Measure	Time frame
A panel of differentially expressed miRNAs can be identified in the blood plasma of different CSU patient groups. A panel of differentially expressed miRNAs enables the identification of responders and non-responders as a predictive biomarker prior to initiation of omalizumab therapy.	—

Secondary

Measure	Time frame
No endpoint	—

Countries

Germany

Contacts

Public ContactTatjana Bobylev

Elbekliniken Stade-BuxtehudeKlinik für Dermatologie

tatjana.bobylev@elbekliniken.de041617036258

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026